Cancer vaccines have shown success in curing tumors in preclinical models. Accumulating
evidence also supports their ability to induce immune responses in patients. In many cases,
these responses correlate with improved clinical outcomes. However, cancer vaccines have
not yet demonstrated their true potential in clinical trials. This is likely due to the difficulty in
mounting a significant anti-tumor response in patients with advanced disease because of
pre-existing tolerance mechanisms that are actively turning off immune recognition in cancer …